AzTrials
AzTrials

Healthy PeoplePhase 4NCT06730620

Bioequivalence Study of Methacholine Chloride

A Phase 4 study testing Test preparation:Methylcholine chloroacetate for inhalation and Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin) in people with Healthy People, run by China-Japan Friendship Hospital at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This trial was divided into two parts. The first part was the PK bioequivalence study in healthy people, which was designed as a single-dose, randomized, open, four-cycle, two-sequence, fully repeated crossover design, and planned to enroll 20 subjects. Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Healthy People
What is being tested?
Test preparation:Methylcholine chloroacetate for inhalation and Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteChina
Study dates
29 Jan 2024to 3 Feb 2024
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Inclusions Criteria

  1. Male or female healthy subjects aged 18 to 50 years old (including 18 and 50 years old).
  2. Male subjects weigh no less than 50 kg, female subjects weigh no less than 45 kg; and body mass index (BMI) = weight (kg) / height 2 (m2), and body mass index is within the range of 18.5~27.0 (including critical values).
  3. Normal pulmonary function test (FEV1 ≥ 80% predicted value, FEV1/FVC ≥ 0.7), FEV1 decline rate after inhalation of saline is no more than 20%, and methacholine chloride provocation test is negative.
  4. Sign the informed consent form before the experiment and fully understand the content, process and possible adverse reactions of the experiment.
  5. Subjects can communicate well with researchers and understand and comply with the requirements of this study.

Exclusions Criteria

  1. Ask for any diseases that might interfere with the test results
  2. Have a history of drug/food allergy
  3. blood collection difficulties or can not tolerate indwelling needle blood collection
  4. Patients who had surgery within 4 weeks prior to the trial or planned to have surgery during the study period
  5. Patients who have used any drug within 2 weeks before the test
  6. Subjects have participated in any drug or medical device clinical study within 3 months prior to screening (except those who failed screening or did not receive any experimental drug).
  7. Blood loss or blood donation exceeding 400 mL in the 3 months prior to screening (excluding female menstrual blood loss), or who intend to donate blood during the trial or within 1 month after the trial.
  8. pregnant and lactating women, or pregnancy test positive.
  9. Male subjects (or their partners) or female subjects had unprotected sex or had a pregnancy plan from 1 week before screening to 3 months after the end of the trial, and were unwilling to use one or more non-drug contraceptive methods (such as total abstinence, contraceptive rings, partner ligation, etc.) during the trial.
  10. Previous history of drug abuse/drug use; Or test positive for drug abuse.
  11. the diet has special requirements, can not comply with the unified diet.
  12. Those who had a smoking history within 6 months before the test, smoked more than 5 cigarettes per day, or were unwilling to give up smoking during the test, or had positive results of nicotine screening.
  13. Alcoholics or regular drinkers in the six months prior to the trial, i.e. drinking more than 14 units of alcohol per week (1 unit =360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine), or breath-positive for alcohol.
  14. Eating a diet within 48 hours prior to taking the study drug that may affect the metabolism of the drug in the body, smoking, drinking behavior, or other diet that the investigator believes may affect the absorption, distribution, metabolism, or excretion of the drug.
  15. Physical examination, electrocardiogram, laboratory examination, vital signs and other tests related to the test were judged by the investigator to be abnormal and clinically significant.
  16. Acute illness or concomitant medication occurred from the screening stage to the study medication.
  17. Subjects who may not be able to complete the study for other reasons or who the investigator believes should not be included

Trial locations and contacts

1 site in 1 country.

China1 site
  • China-japan Friendship Hospital

    Beijing, Beijing Municipality, 100029

Other trials in China

About this study

Official title: Bioequivalence Study of Methacholine for Inhalation

This trial was divided into two parts. The first part was the PK bioequivalence study in healthy people, which was designed as a single-dose, randomized, open, four-cycle, two-sequence, fully repeated crossover design, and planned to enroll 20 subjects.

Conditions
Healthy People
Being tested
Test preparation:Methylcholine chloroacetate for inhalation, Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin)

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Test preparation:Methylcholine chloroacetate for inhalationDrug

    Cholinergic agonists

  • Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin)Drug

    Cholinergic agonists

Study groups in NCT06730620
Study groupRoleWhat they receive
Test preparation:Methylcholine chloroacetate for inhalationExperimentalInhale methacholine solution for 1 minute
Receives: Drug: Test preparation:Methylcholine chloroacetate for inhalation
Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin)Active comparatorInhale methacholine solution for 1 minute
Receives: Drug: Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Peak Concentration

    The highest plasma drug concentration that can be achieved after administration

    Measured: Within 60 minutes before administration and within 3 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 6 hours, and 8 hours after administration

  2. The area under the blood concentration time curve when the time is from 0 to the last time point selected(AUC0-t)

    The area under the blood concentration time curve from 0 to t after administration

    Measured: Within 60 minutes before administration and within 3 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 6 hours, and 8 hours after administration

  3. The area under the blood concentration time curve during time from 0 to infinity(AUC0-∞)

    Area under the blood concentration time curve after medication

    Measured: Within 60 minutes before administration and within 3 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 6 hours, and 8 hours after administration

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Dec 2024
  2. Study start29 Jan 2024
  3. Primary completion3 Feb 2024
  4. Study completion3 Feb 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Crossover
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06730620
Sponsor's protocol ID
TQC3610-BE-01
Status last verified
Dec 2024
First submitted
30 Nov 2024
Last updated
12 Dec 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Test preparation:Methylcholine chloroacetate for inhalation and Reference preparation:Methylcholine chloroacetate for inhalation((Provocholin) in people with Healthy People, run by China-Japan Friendship Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Peak Concentration (time frame: Within 60 minutes before administration and within 3 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 6 hours, and 8 hours after administration). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in